AxoGen (AXGN) Expected to Announce Earnings on Tuesday

AxoGen (NASDAQ:AXGN) will likely be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect AxoGen to post earnings of $0.04 per share and revenue of $49.40 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

AxoGen Trading Down 0.9 %

Shares of AXGN stock opened at $18.51 on Friday. The stock has a market capitalization of $814.45 million, a PE ratio of -57.83 and a beta of 1.00. AxoGen has a 1-year low of $5.55 and a 1-year high of $19.18. The business has a 50-day moving average of $17.21 and a 200 day moving average of $14.65. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group increased their target price on AxoGen from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, February 3rd.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.